Natera Buys Foresight To Boost Super-Early Cancer Detection Tech

Tumor,Microenvironment,Concept,With,Cancer,Cells,,T-cells,,Nanoparticles,,Cancer,Associated

Natera, Inc. (NASDAQ:NTRA) on Friday acquired Foresight Diagnostics, a cancer diagnostics company, for $275 million upfront with an additional $175 million in earnouts tied to the achievement of revenue- and reimbursement-based milestones.

“This acquisition reinforces Natera’s position at the forefront of precision oncology,” said Steve Chapman, chief executive officer of Natera.